PE20212265A1 - Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos - Google Patents
Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismosInfo
- Publication number
- PE20212265A1 PE20212265A1 PE2021001476A PE2021001476A PE20212265A1 PE 20212265 A1 PE20212265 A1 PE 20212265A1 PE 2021001476 A PE2021001476 A PE 2021001476A PE 2021001476 A PE2021001476 A PE 2021001476A PE 20212265 A1 PE20212265 A1 PE 20212265A1
- Authority
- PE
- Peru
- Prior art keywords
- coli
- antigen
- glycosylated
- methods
- bioconjugate
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title abstract 5
- 239000005017 polysaccharide Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 241000588724 Escherichia coli Species 0.000 abstract 6
- 101000702917 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) CDP-abequose synthase Proteins 0.000 abstract 5
- 150000004676 glycans Chemical class 0.000 abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000051366 Glycosyltransferases Human genes 0.000 abstract 1
- 108700023372 Glycosyltransferases Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un bioconjugado de un polisacarido de antigeno O4 glicosilado de E. coli unido covalentemente a una proteina portadora, y sus composiciones. Tambien se proporcionan celulas huespedes recombinantes para producir el bioconjugado, y metodos para producir el bioconjugado usando las celulas huespedes recombinantes. Las celulas huespedes recombinantes contienen un acido nucleico que codifica una glicosil transferasa capaz de modificar el antigeno O4 de E. coli con ramificacion de glucosa para producir el polisacarido de antigeno O4 glicosilado. Los bioconjugados de un polisacarido de antigeno O4 glicosilado de E. coli descritos en este documento pueden usarse solos o en combinacion con uno o mas polisacaridos de antigeno O de E. coli adicionales, para inducir anticuerpos contra un antigeno glicosilado de E. coli y para vacunar a un sujeto contra E. coli patogena extraintestinal (ExPEC)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819746P | 2019-03-18 | 2019-03-18 | |
PCT/US2020/023404 WO2020191082A1 (en) | 2019-03-18 | 2020-03-18 | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20212265A1 true PE20212265A1 (es) | 2021-11-30 |
Family
ID=70285927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001476A PE20212265A1 (es) | 2019-03-18 | 2020-03-18 | Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos |
Country Status (22)
Country | Link |
---|---|
US (2) | US11446370B2 (es) |
EP (1) | EP3941516A1 (es) |
JP (1) | JP7370391B2 (es) |
KR (1) | KR102532707B1 (es) |
CN (1) | CN113924112A (es) |
AR (1) | AR118388A1 (es) |
AU (1) | AU2020240072A1 (es) |
BR (1) | BR112021018236A2 (es) |
CA (1) | CA3134216A1 (es) |
CL (1) | CL2021002426A1 (es) |
CO (1) | CO2021013823A2 (es) |
CR (1) | CR20210522A (es) |
EA (1) | EA202192390A1 (es) |
IL (1) | IL286394A (es) |
JO (1) | JOP20210256A1 (es) |
MA (1) | MA55364A (es) |
MX (1) | MX2021011445A (es) |
PE (1) | PE20212265A1 (es) |
SG (1) | SG11202110301TA (es) |
TW (1) | TWI751513B (es) |
UY (1) | UY38616A (es) |
WO (1) | WO2020191082A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014111516A1 (en) | 2013-01-17 | 2014-07-24 | Arsanis Biosciences Gmbh | Mdr e. coli specific antibody |
LT3110441T (lt) | 2014-02-24 | 2024-04-25 | Glaxosmithkline Biologicals S.A. | Naujas polisacharidas ir jo panaudojimas |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
IL301248B2 (en) * | 2020-09-17 | 2024-04-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and their uses |
CA3203450A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceuticals, Inc. | Analytical method for glycoconjugates using a capillary-based immunoassay system |
CA3215752A1 (en) | 2021-04-01 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Production of e. coli o18 bioconjugates |
CN117098550A (zh) | 2021-04-08 | 2023-11-21 | 杨森制药公司 | 生物缀合物生产方法 |
CN116003531B (zh) * | 2022-12-28 | 2023-09-05 | 山东省农业科学院畜牧兽医研究所 | 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
JP5019494B2 (ja) | 1997-04-01 | 2012-09-05 | コリクサ コーポレーション | モノホスホリルリピドaの水性免疫アジュバント組成物 |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
EP1385541B1 (en) | 2000-04-13 | 2008-06-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
EP1278548A2 (en) | 2000-04-18 | 2003-01-29 | Endobiologics, Incorporated | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US20050287628A1 (en) | 2002-03-07 | 2005-12-29 | Markus Aebi | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
EP2289911A3 (en) | 2004-03-30 | 2011-03-30 | NsGene A/S | Therapeutic use of a growth factor, NsG33 |
AU2006245969B8 (en) | 2005-05-11 | 2011-08-25 | Eth Zurich | Recombinant N-glycosylated proteins from procaryotic cells |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
US8895014B2 (en) | 2008-02-20 | 2014-11-25 | Glycovaxyn Ag | Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells |
EA024697B1 (ru) | 2009-04-27 | 2016-10-31 | Иммурон Лимитед | Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени |
CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
AU2010322454B2 (en) | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
CA2819366A1 (en) | 2010-12-10 | 2012-06-14 | Merck Sharp & Dohme Corp. | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
AU2012306345A1 (en) | 2011-09-06 | 2014-03-20 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
AU2013311534A1 (en) | 2012-09-10 | 2015-03-12 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
EA201590488A1 (ru) | 2012-10-12 | 2015-09-30 | Гликоваксин Аг | Способы модификации клеток-хозяев |
WO2014102265A1 (en) | 2012-12-27 | 2014-07-03 | Glycovaxyn Ag | Methods and compositions relating to crm197 |
WO2014111516A1 (en) | 2013-01-17 | 2014-07-24 | Arsanis Biosciences Gmbh | Mdr e. coli specific antibody |
AP2015008700A0 (en) | 2013-05-18 | 2015-08-31 | Univ California | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
ES2778074T3 (es) | 2013-10-11 | 2020-08-07 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
CA2932225C (en) | 2013-12-04 | 2023-01-17 | Glycovaxyn Ag | Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli |
EP3102599B1 (en) | 2014-02-06 | 2019-02-27 | ARSANIS Biosciences GmbH | E. coli specific antibody sequences |
LT3110441T (lt) | 2014-02-24 | 2024-04-25 | Glaxosmithkline Biologicals S.A. | Naujas polisacharidas ir jo panaudojimas |
MX2016013631A (es) | 2014-04-17 | 2017-02-28 | Glycovaxyn Ag | Celulas huespedes modificadas y usos de las mismas. |
CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
PT3240895T (pt) | 2014-12-30 | 2022-03-02 | Glaxosmithkline Biologicals Sa | Composições e métodos para glicosilação de proteínas |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711635D0 (en) * | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
IL301248B2 (en) | 2020-09-17 | 2024-04-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and their uses |
-
2020
- 2020-03-18 WO PCT/US2020/023404 patent/WO2020191082A1/en active Application Filing
- 2020-03-18 BR BR112021018236A patent/BR112021018236A2/pt unknown
- 2020-03-18 US US16/822,340 patent/US11446370B2/en active Active
- 2020-03-18 CR CR20210522A patent/CR20210522A/es unknown
- 2020-03-18 KR KR1020217033424A patent/KR102532707B1/ko active IP Right Grant
- 2020-03-18 CN CN202080037067.6A patent/CN113924112A/zh active Pending
- 2020-03-18 MA MA055364A patent/MA55364A/fr unknown
- 2020-03-18 AR ARP200100746A patent/AR118388A1/es unknown
- 2020-03-18 EP EP20718989.5A patent/EP3941516A1/en active Pending
- 2020-03-18 UY UY0001038616A patent/UY38616A/es unknown
- 2020-03-18 MX MX2021011445A patent/MX2021011445A/es unknown
- 2020-03-18 JO JOP/2021/0256A patent/JOP20210256A1/ar unknown
- 2020-03-18 CA CA3134216A patent/CA3134216A1/en active Pending
- 2020-03-18 EA EA202192390A patent/EA202192390A1/ru unknown
- 2020-03-18 SG SG11202110301TA patent/SG11202110301TA/en unknown
- 2020-03-18 TW TW109109075A patent/TWI751513B/zh active
- 2020-03-18 JP JP2021556247A patent/JP7370391B2/ja active Active
- 2020-03-18 AU AU2020240072A patent/AU2020240072A1/en active Pending
- 2020-03-18 PE PE2021001476A patent/PE20212265A1/es unknown
-
2021
- 2021-09-14 IL IL286394A patent/IL286394A/en unknown
- 2021-09-16 CL CL2021002426A patent/CL2021002426A1/es unknown
- 2021-10-14 CO CONC2021/0013823A patent/CO2021013823A2/es unknown
-
2022
- 2022-07-28 US US17/815,705 patent/US11931405B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW202102255A (zh) | 2021-01-16 |
US11931405B2 (en) | 2024-03-19 |
JP7370391B2 (ja) | 2023-10-27 |
KR102532707B1 (ko) | 2023-05-12 |
MX2021011445A (es) | 2021-10-13 |
MA55364A (fr) | 2022-01-26 |
CO2021013823A2 (es) | 2022-03-29 |
JOP20210256A1 (ar) | 2023-01-30 |
EA202192390A1 (ru) | 2021-12-03 |
CL2021002426A1 (es) | 2022-04-29 |
KR20210141586A (ko) | 2021-11-23 |
EP3941516A1 (en) | 2022-01-26 |
AU2020240072A1 (en) | 2021-10-28 |
SG11202110301TA (en) | 2021-10-28 |
WO2020191082A1 (en) | 2020-09-24 |
US11446370B2 (en) | 2022-09-20 |
JP2022533883A (ja) | 2022-07-27 |
CR20210522A (es) | 2021-12-17 |
CN113924112A (zh) | 2022-01-11 |
US20200316184A1 (en) | 2020-10-08 |
AR118388A1 (es) | 2021-09-29 |
CA3134216A1 (en) | 2020-09-24 |
WO2020191082A9 (en) | 2020-11-05 |
IL286394A (en) | 2021-10-31 |
US20230118878A1 (en) | 2023-04-20 |
TWI751513B (zh) | 2022-01-01 |
UY38616A (es) | 2020-09-30 |
BR112021018236A2 (pt) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20212265A1 (es) | Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos | |
EA201691478A1 (ru) | Новый полисахарид и его применения | |
PH12020551907A1 (en) | Antagonizing cd73 antibody | |
AR118389A1 (es) | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización | |
NZ711567A (en) | Antibody formulations | |
WO2016107818A8 (en) | Compositions and methods for protein glycosylation | |
NO20083266L (no) | Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser | |
BR112014018630A2 (pt) | alvejamento de glicanos de sulfato de condroitina | |
PE20190394A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
CY1123403T1 (el) | Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων | |
BR112019007803A2 (pt) | formulações de vacina de glicoconjugado contra expec | |
AR095418A1 (es) | Métodos para aumentar el contenido de manosa en proteínas recombinantes | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer | |
BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
PE20081687A1 (es) | Proteina de fusion | |
EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
TWD204989S (zh) | 連接器 | |
CO2020000231A2 (es) | Composiciones inmunogénicas que comprenden cea muc1 y tert | |
TWD204990S (zh) | 連接器 | |
MX2019009063A (es) | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. | |
BR112022006550A2 (pt) | Composições de escherichia coli e seus métodos | |
AR112757A1 (es) | Composiciones inmunogénicas | |
MX2020002730A (es) | Metodos de preparacion de composiciones que contienen timoquinona. | |
BR112018068865A2 (pt) | plataforma e vacinas de antígeno de fusão multiepítopo de ponta de adesina e seu uso no tratamento de diarreia enterotoxigênica |